Diabetic Retinopathy Therapeutics Pipeline Analysis 2017

Diabetic retinopathy therapeutic pipeline analysis is projected to grow as perceived by the current situation of increasing prevalence of diabetes, globally. Some of the main factors driving the pipeline analysis for diabetic retinopathy include obesity, incidence of diabetes mellitus, stress conditions and increasing prevalence of diabetic retinopathy, low market penetration since a limited number of companies are making an analog and increasing awareness of health issues. According to the data by National Eye Institute, the prevalence of diabetic retinopathy has been increasing mainly in Hispanic and white population. The disease affects equally in both male and female.

Explore Report at: https://www.psmarketresearch.com/market-analysis/diabetic-retinopathy-therapeutics-pipeline-analysis

Diabetic retinopathy is a type of an eye disease, that affect mostly people with diabetes. The other condition associated with the disease include cataract, diabetic macular edema and glaucoma. All these conditions are have the potential to cause blindness and vision loss. Diabetic retinopathy leads to leakage of blood vessels which distort the vision and sometimes swelling occurs in macula region in case of diabetic macular edema. The major cause of diabetic retinopathy is high blood sugar level which damages the tiny blood vessels in retina, and can also cause haemorrhage. Diabetic retinopathy can occur in four stages namely; mild, moderate, severe and proliferative diabetic retinopathy. In mild conditions swelling of retina blood vessels occur which become distorted in moderate stage due to blockage of blood flow. This leads to the growth of new blood vessels in severe case and in proliferative stage, retinal detachment occurs which can lead to permanent vision loss. Diabetic retinopathy can be diagnosed by visual acuity testing, pupil dilation, tonometry and optical coherence tomography.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/diabetic-retinopathy-therapeutics-pipeline-analysis/toc-sample

Some of the companies having a pipeline of diabetic retinopathy therapeutics include Bayer, Novartis, F. Hoffmann-La Roche, Alimera Science, Valeant Pharmaceutical, Inc., Abbott Laboratories, Pfizer, Inc. Regeneron Pharmaceutical, ThromboGenics, Inc., Ampio Pharmaceuticals, Inc.

Leave a Reply

Designed by CyFocus.com
Powered by CyFocus.net